<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897088</url>
  </required_header>
  <id_info>
    <org_study_id>TILD-18-20</org_study_id>
    <nct_id>NCT03897088</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to assess the&#xD;
      efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the&#xD;
      scalp.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with Investigator Global Assessment mod 2011 (scalp) score of &quot;clear&quot; and &quot;almost clear&quot; with at least 2-point reduction from Baseline at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with incidence, seriousness and severity of all adverse events.</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with severe infections, whether or not reported as a serious event</measure>
    <time_frame>Week 72</time_frame>
    <description>defined as any infection meeting regulatory definition of serious adverse event, or any infection requiring intravenous antibiotics whether or not reported as a serious event as per the regulatory definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with malignancies (excluding carcinoma in situ of the cervix).</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with melanoma skin cancer.</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with Major Adverse Cardiovascular Events</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with study treatment-related hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, etc.).</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with injection site reactions (eg, pain, erythema, edema etc).</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects with non-melanoma skin cancer</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least 90% improvement from Baseline in the Psoriasis Scalp Severity Index at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in Psoriasis Scalp Severity Index score from Baseline to Week 16.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving Psoriasis Scalp Severity Index 75 at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving Psoriasis Scalp Severity Index 100 at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in scalp surface area involvement from Baseline to Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 75% reduction in Psoriasis Scalp Severity Index during 16-week placebo-controlled treatment period.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Investigator Global Assessment mod 2011 (scalp ) response during the 16-week placebo-controlled treatment period.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a 4-point reduction in Itch Numeric Rating Scale score from Baseline to Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving Psoriasis Area and Severity Index 75, Psoriasis Area and Severity Index 90, and Psoriasis Area and Severity Index 100 at week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Investigator Global Assessment mod 2011 score (whole body) and Physician's Global Assessment score (whole body) score of &quot;clear&quot; or &quot;almost clear&quot; with at least a 2-point reduction from Baseline to Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in total body surface area involvement from Baseline to week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Investigator Global Assessment (scalp only) score of &quot;clear&quot; and &quot;almost clear&quot; with at least 2-point reduction from Baseline at Week 16.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment mod 2011 (scalp and whole body), Psoriasis Scalp Severity Index, Investigator Global Assessment (scalp only), Scalp Itch NRS, Psoriasis Area and Severity Index, Physician Global Assessment for skin (whole body).</measure>
    <time_frame>Week 52</time_frame>
    <description>Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with IGA (scalp only) score of &quot;clear&quot; and &quot;almost clear&quot; with at least 2-point reduction from Baseline</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with IGA mod 2011 (scalp) score of &quot;clear&quot; and &quot;almost clear&quot; with at least 2-point reduction from Baseline</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least 90% improvement from Baseline in the Psoriasis Scalp Severity Index</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index score (total and 6 domain scores) at measured time points through week 52</measure>
    <time_frame>Week 52</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Scalp Psoriasis</condition>
  <arm_group>
    <arm_group_label>Tildrakizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 3: Observational Safety Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects will not receive study treatment during the follow-up period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PART 1: Double-blind Placebo-controlled</intervention_name>
    <description>all eligible subjects will receive either tildrakizumab or placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tildrakizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PART 2: Double-blind Active Treatment Extension</intervention_name>
    <description>subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule</description>
    <arm_group_label>Tildrakizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects should be 18 years or older at the time of signing the informed consent&#xD;
             during the Screening visit.&#xD;
&#xD;
          2. Subjects with a clinical diagnosis of chronic plaque psoriasis of at least 6 months&#xD;
             (as determined by-subject interview and confirmation of diagnosis through physical&#xD;
             examination by Investigator).&#xD;
&#xD;
          3. Subjects must have moderate to severe plaque psoriasis of the scalp at Screening and&#xD;
             at Baseline, defined by:&#xD;
&#xD;
               -  Scalp Investigator Global Assessment (IGA) of ≥3&#xD;
&#xD;
               -  Psoriasis Scalp Severity Index (PSSI) score of ≥12&#xD;
&#xD;
               -  ≥30% or scalp surface area affected.&#xD;
&#xD;
          4. Subject must have moderate to severe plaque psoriasis at Screening and Baseline&#xD;
             defined by&#xD;
&#xD;
               -  Physician Global Assessment for Skin (PGA-S) of at least moderate severity (score&#xD;
                  of ≥3 on a 5-pointer scale)&#xD;
&#xD;
               -  PASI score of ≥12&#xD;
&#xD;
               -  Body Surface Area (BSA) involvement of &gt;10%&#xD;
&#xD;
          5. Subjects must be considered candidates for systemic therapy, meaning scalp psoriasis&#xD;
             inadequately controlled by topical treatments (corticosteroids), and/or phototherapy,&#xD;
             and/or previous systemic therapy.&#xD;
&#xD;
          6. Subjects has a negative evaluation for tuberculosis (TB) within 4 weeks before&#xD;
             initiating study treatment, defined as a negative QuantiFERON® test. Subjects with a&#xD;
             positive or 2 successive indeterminate. QuantiFERON® tests are allowed if they have&#xD;
             all of the following:&#xD;
&#xD;
               -  No history of active TB or symptoms of TB.&#xD;
&#xD;
               -  A posterior-anterior chest radiogram (with associated report available at study&#xD;
                  center) performed within 3 months of Screening with no evidence of active TB (or&#xD;
                  of any other pulmonary infectious diseases).&#xD;
&#xD;
               -  If prior latent TB infection (LTBI), must have history of adequate prophylaxis&#xD;
                  (per local standard of care).&#xD;
&#xD;
               -  If presence of LTBI is established, then treatment according to local country&#xD;
                  guidelines must have been followed for 4 weeks prior to inclusion in the study.&#xD;
&#xD;
             A maximum of 2 QuantiFERON® tests are allowed. A re-test is only permitted if the&#xD;
             first is indeterminate; the result of the second test will then be used.&#xD;
&#xD;
          7. Subjects are unlikely to conceive, as indicated by at least one &quot;Yes&quot; answer to the&#xD;
             following questions:&#xD;
&#xD;
               -  Subject is a male.&#xD;
&#xD;
               -  Subject is a female and agrees to abstain from heterosexual activity OR use a&#xD;
                  highly effective method of contraception as per Appendix 7.&#xD;
&#xD;
               -  Male subjects with female partners of childbearing potential who are not using&#xD;
                  birth control as described above must use a barrier method of contraception (eg,&#xD;
                  condom) if not surgically sterile (ie, vasectomy).&#xD;
&#xD;
               -  Subject is a surgically sterilized female or is documented to be postmenopausal.&#xD;
                  For contraceptive guidance see Appendix 7.&#xD;
&#xD;
          8. For women of childbearing potential, a negative serum pregnancy test at Screening and&#xD;
             a negative urine pregnancy test within 24 hours prior to Day 1 and on subsequent&#xD;
             visits at which study treatment doses are scheduled.&#xD;
&#xD;
          9. Subjects must have results of a physical examination within normal limits or&#xD;
             clinically acceptable limits to the Investigator prior to Day 1. The Investigator is&#xD;
             encouraged to consult with the Medical Monitor (or appropriate designee) if there are&#xD;
             questions regarding the significance of any out-of-range values.&#xD;
&#xD;
         10. Subjects must be capable of giving signed informed consent as described in Appendix 2,&#xD;
             which includes compliance with the requirements and restrictions listed in the ICF and&#xD;
             in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have laboratory abnormalities at Screening including any of the&#xD;
             following:&#xD;
&#xD;
               -  Alanine aminotransferase or aspartate aminotransferase ≥2.5 × the upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  Creatinine ≥2 × the upper limit of normal&#xD;
&#xD;
               -  Serum direct bilirubin ≥1.5 mg/dL&#xD;
&#xD;
               -  White blood cell count &lt;3.0×103/μL&#xD;
&#xD;
               -  Any other laboratory abnormality, which, in the opinion of the Investigator, will&#xD;
                  prevent the subject from completing the study or will interfere with the&#xD;
                  interpretation of the study results.&#xD;
&#xD;
          2. Subjects who have predominantly non-plaque forms of psoriasis specifically&#xD;
             erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or&#xD;
             medication-exacerbated psoriasis, or new-onset guttate psoriasis.&#xD;
&#xD;
          3. Women of childbearing potential who are pregnant, intend to become pregnant (within 6&#xD;
             months of completing the study), or are lactating.&#xD;
&#xD;
          4. Subjects with any infection or history of recurrent infection requiring treatment with&#xD;
             systemic antibiotics within 2 weeks prior to Screening, or severe infection (eg,&#xD;
             pneumonia, cellulitis, bone or joint infections) requiring hospitalization or&#xD;
             treatment with intravenous (IV) antibiotics within 6 weeks prior to Screening.&#xD;
&#xD;
          5. Subjects with any previous use of tildrakizumab or other IL-23/Th-17 pathway&#xD;
             inhibitors, including p40, p19 and IL-17 antagonists for psoriasis.&#xD;
&#xD;
             • Prior use of TNF-alpha inhibitors with a wash-out period of 12 weeks would be&#xD;
             allowed. However, the number of subjects with prior use of TNF-alpha inhibitors would&#xD;
             be capped at 40% and the analysis will be stratified based on prior use of these&#xD;
             biologics.&#xD;
&#xD;
          6. Subjects with a positive human immunodeficiency virus test result, hepatitis B surface&#xD;
             antigen, or hepatitis C virus test result.&#xD;
&#xD;
          7. Subjects with a prior malignancy or concurrent malignancy (excluding successfully&#xD;
             treated basal cell carcinoma, squamous cell carcinoma of the skin in situ, squamous&#xD;
             cell carcinoma of skin with no evidence of recurrence within 5 years or carcinoma in&#xD;
             situ of the cervix that has been adequately treated).&#xD;
&#xD;
          8. Subjects who have received live viral or bacterial vaccination within 4-weeks prior to&#xD;
             Baseline or who intend to receive live viral or bacterial vaccination during the&#xD;
             study.&#xD;
&#xD;
          9. Subjects who are currently participating in another interventional clinical study or&#xD;
             has participated in an interventional clinical study within 5-half-lives (of the drug)&#xD;
             to wash-out prior to randomization (Subjects participating in observational studies or&#xD;
             non-interventional registry studies may be included in the study).&#xD;
&#xD;
         10. Subjects or a family member is among the personnel of the study center or&#xD;
             Sponsor/designee staff directly involved with this study.&#xD;
&#xD;
         11. Subjects who have any concomitant medical condition which in the opinion of the&#xD;
             Investigator could affect the study outcome or present an unacceptable risk.&#xD;
&#xD;
         12. Subjects who were hospitalized due to an acute cardiovascular event (such as&#xD;
             myocardial infarction, cerebrovascular accident, cardiovascular illness [eg, angina&#xD;
             pectoris], or cardiovascular surgery [such as coronary artery bypass grafting]) within&#xD;
             6 months before Screening.&#xD;
&#xD;
         13. Subjects who, in the opinion of the Investigator, will not be a reliable participant&#xD;
             in the study and those who can confound the results of the study.&#xD;
&#xD;
         14. Subjects who have a history of alcohol or drug abuse in the previous year.&#xD;
&#xD;
         15. Subjects who have high risk of suicidality at the Screening assessment based on&#xD;
             Investigator's judgment or, if appropriate, as indicated by a response of &quot;yes&quot; within&#xD;
             the last 12 months to Questions 4 or 5 in the suicidal ideation section, or any&#xD;
             positive response in the behavioral section of the Columbia-Suicide Severity Rating&#xD;
             Scale&#xD;
&#xD;
         16. Subjects with any other clinically significant laboratory abnormality, which, in the&#xD;
             opinion of the Investigator, will prevent the subject from completing the study or&#xD;
             will interfere with the interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 18</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 7</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 3</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 12</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 9</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 2</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 14</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 21</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 19</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 5</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 13</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 4</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 16</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 01</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 20</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 8</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 17</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 11</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 6</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 23</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 27</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 26</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 25</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 24</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 22</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

